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No specific vaccine for West Nile virus (WNV) is currently available for human use. In the present study, we
describe the generation of WNV-like particles (WNV-LPs) in insect cells by use of recombinant baculoviruses
expressing the WNV structural proteins prME or CprME. BALB/c mice immunized with purified WNV-LPs
developed WNV-specific antibodies that had potent neutralizing activities. Mice immunized with prME-like
particles (prME-LPs) showed no morbidity or mortality after challenge with WNV. Immunization with prME-
LPs can induce sterilizing immunity without producing any evidence of viremia or viral RNA in the spleen
or brain. These results suggest that WNV-LPs hold promise as a vaccine candidate for WNV infection.
There is an urgent need for an effective prophylactic
vaccine to prevent West Nile virus (WNV) transmission
and infection in domestic animals and humans. A
killed-virus equine vaccine is in use [1]; however, no
human vaccine has been approved. Although passive
immunotherapy has been shown to be effective in
mouse models [2, 3], its use has been limited in humans
[4]. Neither a treatment option nor a proven vaccine
for the prevention of WNV infection is available at the
present time. Several approaches to the development
of a WNV vaccine have demonstrated immunogenicity
and protective efficacy, including chimeric [5, 6], DNA
[7, 8], and live attenuated vaccines [9]. Virus-like par-
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ticles (VLPs) synthesized in various expression systems
have been used to prevent infection with papilloma-
viruses [10] and rotaviruses [11]. Such an approach has
also been successfully extended to other important hu-
man pathogens, such as flaviviruses [12–14]. In the
present study, we report the production of WNV-like
particles (WNV-LPs) containing the WNV structural
proteins, prME and CprME, by use of a recombinant
baculovirus in insect cells, and we evaluate the use of
WNV-LPs as a vaccine in a mouse model.
MATERIALS AND METHODS
Recombinant baculovirus expressing WNV prME and
CprME was generated by use of the Bac-to-Bac bac-
ulovirus expression system (Invitrogen), as described
elsewhere [15]. cDNA (GenBank accession number
AF202541) for prME (nt 335–2427) and CprME (nt 1–
2636) was generated from WNV strain HNY1999–in-
fected Vero cells by polymerase chase reaction (PCR)
with the following 2 primer sets: for prME, 5′-CTATCA-
ATCGGCGGAGCTC-3′ and 5′-ACCCAGTGTCAGCG-
TGCA-3′, and for CprME, 5′-GCGGGATCCTAATAC-
GACTCACTATAGGGAGTAGTTCGCCTGTGTGAG-
CTG-3′ and 5′-GCTTCCCACATTTGRTGYTC-3′. These
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PCR-generated fragments were then cloned into the pGEM-T
Easy vector (Promega). pFASTBac-prME and pFASTBac-CprME
were generated by subcloning an EcoR1 and SpeI fragment into
the pFASTBac-1 vector (Invitrogen). The correct recombinant
baculoviruses were identified by immunofluorescence and im-
munoblotting with a rabbit anti-E antibody. The procedure for
the production and purification of WNV-LPs was similar to that
for hepatitis C virus–like particles (HCV-LPs) [15], with some
modifications (see the Appendix in the electronic edition). The
WNV recombinant proteins prM, E, and NS1 were produced,
and rabbit antibodies against them were generated, as described
in the Appendix in the electronic edition.
Four groups of 6 BALB/c mice (6–8-week-old females; Jack-
son Laboratories) were immunized 4 times at 3-week intervals.
Mice received injections of 20 mg of WNV-LPs into each quad-
riceps muscle in 100 mL of PBS, on the basis of the previously
described immunization protocol for HCV-LPs [14]. One
group received prME-like particles (prME-LPs) alone; a second
group received prME-LPs plus AS01B (50 mL); a third group
received CprME-like particles (CprME-LPs) alone; and a final
group received AS01B (50 mL) alone. The adjuvant AS01B,
which contains monophosphoryl lipid A and QS21, was pro-
vided by GlaxoSmithKline. Serum samples were collected be-
fore immunization and 2 weeks after each immunization and
were analyzed for anti-M, -E, or -NS1 antibodies by both ELISA
and virus neutralization assay (see the Appendix in the elec-
tronic edition).
Mice were housed in biosafety level–3 conditions and were
given food and water ad libitum. Mice were acclimatized for
at least 1 week before challenge. Immunized mice and 6 age-
matched, female BALB/c mice were inoculated intraperitoneally
with 104 pfu of WNV that had been derived from an infectious
clone [16]. A group of 6 age-matched, female BALB/c mice
were inoculated with diluent alone (PBS, 1% fetal bovine se-
rum). Mice were weighed and were scored daily for clinical
signs of disease, including ruffled fur, hunching, and paresis.
Morbidity was defined as exhibition of 110% weight loss and/
or clinical signs for 2 days. Mice that exhibited severe disease
were killed. Surviving mice were killed 31 days after inoculation.
Mice were bled on day 3 after inoculation. Spleens and brains
were harvested from mice at death or on the day of killing,
and blood was also harvested from mice that were killed. Brains
were divided sagitally at the midline. One-half of each brain
was processed for RNA extraction, as described elsewhere [17].
The RNA from serum, spleens, and brains were analyzed for
WNV in the envelope gene by real-time reverse-transcription
PCR (RT-PCR) with primers, as described elsewhere [17]. RNA
copies were quantified by use of a standard curve of 50–
copies of RNA per reaction and are reported as the55 10
number of copies per milliliter of serum or per gram of tissue.
The thresholds of detection for serum, spleen, and brain as-
says were copies/mL, copies/g, and3 4 35 10 1.5 10 7.5 10
copies/g, respectively. Virus was titered by use of Vero cells [17].
Fixed brains were sectioned, stained with hematoxylin-eosin
(HE), and blindly assessed for abnormalities by light microscopy.
RESULTS AND DISCUSSION
Recombinant baculoviruses bvWNVprME and bvWNVCprME
(figure 1A), which contain the coding sequences for prM and
E and for core, prM, and E, respectively, were shown to direct
the production of WNV-LPs in insect cells. By use of a modified
method described elsewhere for HCV-LPs [15], WNV-LPs were
harvested and purified by iodixanol gradient centrifugation (see
the Appendix in the electronic edition). WNV E protein was
detected by ELISA (figure 1B). The peak of E reactivity cor-
responds to the peak total protein concentration and to buoyant
densities of 1.12–1.14 g/mL. Western blot analysis (figure 1C)
revealed that these fractions contained a 50-kDa E protein band
and a 20-kDa prM protein band in both the prME-LP and
CprME-LP preparations. The mature form of M protein was
not detected, probably because the furin required for the proper
cleavage of prM to M is not expressed efficiently in Sf9 insect
cells [18]. A core protein band was also detected at 12 kDa in
the CprME-LP preparation (data not shown). Examination by
cryoelectron microscopy revealed that WNV-LPs are polymor-
phic in appearance and have a diameter of 40–60 nm (figure
1D). The typical yield of WNV-LPs from the procedure is ∼1–
2 mg/100 mL of culture, which is substantially greater than the
reported yields of other flavivirus-like particles generated in
mammalian cells [12, 19].
Groups of BALB/c mice ( ) were immunized withnp 6
prME-LPs alone, CprME-LPs alone, prME-LPs plus AS01B, or
AS01B alone, with 4 injections given at 3-week intervals. Al-
though all of the mice immunized with prME-LPs (with or
without the AS01B adjuvant) developed anti-E antibodies after
the fourth immunization, AS01B enhanced the anti-E antibody
response significantly, from 317 to 8128, and also enhanced the
anti-M antibody response, from 50 to 142 (table 1). CprME-
LPs induced weaker antibody responses to the M and E pro-
teins. One mouse in the AS01B group died of unknown causes
after the first immunization.
The pooled serum samples collected from each group at 2
weeks after the fourth immunization were assayed for titers of
neutralizing antibodies (table 1). Titers were determined to be
37 in the prME-LP group and 75 in the prME-LP plus AS01B
group. The CprME-LP group did not develop detectable titers
of neutralizing antibody. None of the serum samples from the
AS01B group had any detectable antibodies to the E and M
proteins or neutralizing antibodies to WNV.
Immunized mice were challenged with 104 pfu of WNV. This
dose is 1100 times the ID50 identified in a previous study in
6-month-old BALB/c mice (data not shown), and it was chosen
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Figure 1. Construction and production of West Nile virus–like particles (WNV-LPs) in insect cells. A, Map depicting segments of the WNV genome
in the recombinant baculovirus expression vector; the bvWNVprME construct (top) contains the coding sequences for prM and E, and the bvWNVCprME
construct (bottom) contains the coding sequences for core, prM, and E. pPolh, baculovirus polyhedrin promoter; SV40pA, simian virus 40 polyadenylation
sequence. B, Characterization of WNV-LPs. WNV-LPs were purified from Sf9 insect cells by iodixanol gradient centrifugation. Ten fractions collected
from the top of the gradient were analyzed for total protein content and the titer of WNV E protein by ELISA. C, Western blot analysis of purified
prME-like particles (prME-LPs) and CprME-like particles (CprME-LPs) with rabbit anti-E or -M antibodies. Uninfected Vero cells and hepatitis C virus–
like particles (HCV-LPs) were used as negative controls, and WNV-infected Vero cells were used as a positive control. D, Cryoelectron micrograph
(CM) of purified prME-LPs. Bar, 100 nm.
to enhance the probability of discriminating differences in mor-
bidity among groups. Mice were challenged 2 months after the
fourth immunization (table 2). Two groups of unimmunized
mice (6 mice each) of similar age were included as control mice
in this challenge experiment. One group was challenged with
the same dose of WNV as were the immunized groups, and
the other group was not challenged. Morbidity and mortality
in the unimmunized/challenged group were 50% and 17%,
respectively. There was no morbidity or mortality in either the
prME-LP group or the prME-LP plus AS01B group. In contrast,
67% morbidity was observed in the CprME-LP group. The
presence of high titers of anti-E antibodies before challenge
correlated with protective immunity, and all mice had a further
increase in titers of anti-E antibodies after challenge, a result
consistent with the presence of an anamnestic response directed
toward the VLPs, of which the E protein is the major immu-
nogenic component. All of the surviving mice were examined
for pathologic abnormalities in the brain at the time of killing
on day 31 after challenge. HE-stained brain sections showed
no significant neuropathologic damage.
Viral replication was analyzed after challenge, to determine
whether immunization with WNV-LPs induced sterilizing pro-
tective immunity. Viremia was assayed during the peak viremic
phase on day 3 after challenge (table 2 and, in the electronic
edition, figure 2). Because it is possible that the immunized
mice had neutralizing antibodies by day 3, viremia was mea-
sured by both plaque-forming assay and RT-PCR. Postchallenge
viremia (infectious virus or viral RNA) was detected in all 6
of the mice in the unimmunized/challenged group, in 5 (83%)
of the 6 mice in the CprME-LP group, and in 4 (67%) of the
6 mice in the prME-LP group; however, 0 of the 6 mice in the
prME-LP plus AS01B group had circulating infectious virus or
viral RNA in serum after challenge. Although 4 of the 6 mice
in the prME-LP group had viral nucleic acid (as detected by
RT-PCR), only 2 had infectious virus (as detected by plaque-
forming assay). In addition, the geometric mean viral titer of
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Unimmunized/unchallenged ND !50 ND !50 0/6 ND 0
Unimmunized/challenged ND 2432 ND !50 4/5 ND 15
AS01B !50 3200 !50 !50 4/4 0 37
prME-LPs 317 5689 !50 89 3/6 37 62
prME-LPs plus AS01B 8128 45,709 112 355 1/6 75 75
CprME-LPs 86 7217 !50 !50 5/6 0 57
NOTE. Serum antibody titers were determined after the last of 4 immunizations. For each group, the geometric mean of antibody titers was
calculated. The titer for a mouse with a negative ELISA value at a serum dilution of 50 was arbitrarily set at 50 for the calculation of the geometric
mean. The results of statistical analyses were as follows (by Mann-Whitney U test or Fisher’s exact test). Anti-WNV E titer before challenge:
, for prME-like particles (prME-LPs) vs. AS01B; , for prME-LPs plus AS01B vs. AS01B; and , for prME-LPs vs. prME-Pp .018 Pp .0009 Pp .026
LPs plus AS01B. NS1 seroconversion: , for prME-LPs vs. AS01B, and , for prME-LPs plus AS01B vs. AS01B. Neutralization titerPp .024 Pp .001
before challenge: , for prME-LPs vs. AS01B, and , for prME-LPs plus AS01B vs. AS01B. CprME-LPs, CprME-like particles; ND,Pp .0007 Pp .0003
not done.
Table 2. Protection of mice immunized with West Nile virus–like particles (WNV-LPs) from challenge
with WNV.
Mouse group Virus Morbidity Mortality
WNV detected in
Seruma Serumb Spleenc Brainc
Unimmunized/unchallenged Mock (diluent) 0/6 0/6 0/6 0/6 0/6 0/6
Unimmunized/challenged WNV 3/6 1/6 5/6 6/6 6/6 3/6
AS01B WNV 2/5 1/5 4/5 4/5 5/5 2/5
prME-LPs WNV 0/6 0/6 2/6 4/6 2/6 0/6
prME-LPs plus AS01B WNV 0/6 0/6 0/6 0/6 0/6 0/6
CprME-LPs WNV 4/6 0/6 5/6 5/6 5/6 3/6
NOTE. Data are proportion of mice. Two months after the last of 4 immunizations, mice were challenged intraperitoneally
with 104 pfu of WNV. The results of statistical analyses are as follows (by Fisher’s exact test; control combines the results from
the unimmunized/challenged and AS01B groups). Morbidity: , for prME-like particles (prME-LPs) vs. control, andPp .03 Pp
, for prME-LPs plus AS01B vs. control. WNV detected in serum by plaque-forming assay: , for prME-LPs vs. control,.03 Pp .04
and , for prME-LPs plus AS01B vs. control. WNV detected in serum by reverse-transcription polymerase chain reactionPp .0016
(RT-PCR): , for prME-LPs plus AS01B vs. control, and , for prME-LPs vs. prME-LPs plus AS01B. WNV detectedPp .0002 Pp .01
in spleen: , for prME-LPs vs. control, and , for prME-LPs plus AS01B vs. control. WNV detected in brain:Pp .007 Pp .0005
, for prME-LPs vs. control, and , for prME-LPs plus AS01B vs. control. CprME-LPs, CprME-like particles.Pp 0.003 Pp .003
a Positive for infectious WNV by plaque-forming assay on day 3 after challenge.
b Positive for viral RNA by RT-PCR on day 3 after challenge.
c Positive for viral RNA on day of death or killing.
the prME-LP group ( copies/mL) was more than an41.58 10
order of magnitude lower than that of the unimmunized/chal-
lenged group ( copies/mL) ( ).52 10 Pp .027
As an additional measure of postchallenge viral replication,
the presence of viral RNA in the spleen and brain was deter-
mined at the time of death or at killing (day 31 after challenge).
Viral RNA was detected in the brains of ∼50% of the mice in
the unimmunized/challenged, AS01B, and CprME-LP groups
(table 2). In contrast, none of the mice that received either
prME-LPs alone or prME-LPs plus AS01B had detectable viral
RNA in the brain, suggesting that these mice were protected
from neuroinvasion. Viral RNA was detected in the spleens of
all of the mice in the unimmunized/challenged and AS01B
groups, providing evidence for active replication in these con-
trol groups. Viral RNA was detected in 2 of the 6 and 5 of the
6 mice in the prME-LP and CprME-LP groups, respectively,
but in 0 of the mice in the prME-LP plus AS01B group. Thus,
viral replication was partially inhibited in the mice immunized
with prME-LPs alone and was completely inhibited in the mice
immunized with prME-LPs plus AS01B.
Seroconversion to the WNV nonstructural protein NS1 was
assayed after viral challenge. Eight of the 9 mice in the un-
immunized/challenged and AS01B groups and 5 of the 6 mice
in the CprME-LP group developed an anti-NS1 antibody re-
sponse after challenge with WNV (table 2). In contrast, only
3 of the 6 mice in the prME-LP group and 1 of the 6 mice in
the prME-LP plus AS01B group seroconverted to anti-NS1 an-
tibody, indicating that immunization with prME-LPs (espe-
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cially in the presence of adjuvant) prevented productive infec-
tion and, therefore, exposure to NS1 after challenge with WNV.
These results, together with the lack of detectable viremia and
viral RNA in the spleens, suggest that sterilizing immunity
might be achieved in mice immunized with prME-LPs.
It is not apparent why the CprME particles, differing from
the prME particles only in the addition of core protein, are less
immunogenic. One explanation could be that the CprME prep-
aration is less pure, resulting in lower immunogenicity. It is
also possible that the particles formed by the CprME construct
are less immunogenic because of the subtle structural differ-
ence. Alternatively, the core protein may somehow diminish
the immune response to the VLPs.
It is interesting to note that the neutralization titer in the
mice immunized with prME-LPs plus AS01B did not increase
after challenge, probably because the preexisting neutralization
titer was sufficient to protect the mice from infection. It is
conceivable that cell-mediated immunity induced by immu-
nization with VLPs might contribute to the observed sterilizing
immunity [14]. The relative contribution of humoral versus
cellular components in the protective immunity observed here
awaits future study.
Several published studies have described promising ap-
proaches to vaccine development for WNV. Chimeric or at-
tenuated flaviviruses that are closely related to WNV have been
shown to successfully protect animals from WNV infection [5,
6, 9]. DNA immunization by use of plasmid-expressing WNV
proteins [7] and Kunjin virus [8] have also been applied suc-
cessfully in the animal model. Despite the promise of these
vaccine candidates, safety concerns will always be an issue.
However, VLP-based vaccines are noninfectious and are easily
controlled for quality and safety. The recent successful devel-
opment of a human papillomavirus vaccine based on VLP tech-
nology [10] lends credence to the promise of this approach in
the development of an effective WNV vaccine.
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